自"阿尔法折叠2"颠覆蛋白质结构预测以来，人工智能（AI）技术在治疗性抗体设计领域展现出前所未 有的应用潜力。 《自然》网站在近日的报道中指出，近年来，多个科研团队利用自主开发的AI工具，辅助设计并成功 制备出多种功能各异的治疗性抗体。不过，专家同时提醒，这些抗体的安全性与有效性仍需进一步验 证。 抗体药物市场巨大 抗体是免疫系统中识别特定靶标并激发保护性反应的关键蛋白质。与所有蛋白质相同，抗体由氨基酸链 折叠形成复杂的三维空间结构，既能阻断病原体侵入细胞，也可标记异常细胞引导免疫系统清除，还能 用于递送药物或抑制疾病相关蛋白质的活性。目前全球已有160余种工程化抗体获批用于癌症、感染性 疾病及自身免疫性疾病的治疗。 英国牛津大学旗下《抗体治疗》杂志2022年的分析数据显示，随着数千种新型抗体不断涌现，预计到 2028年，全球抗体药物市场年收入将突破4550亿美元。正如诺贝尔奖得主、美国华盛顿大学蛋白质设计 专家戴维·贝克所言："抗体已成为制药领域的硬通货。" 然而，传统抗体开发流程通常面临周期长、成本高、挑战大的困境。候选抗体需经历多轮优化，才能具 备理想药物的特性，包括良好的溶解性、高度的特异性以及避免脱 ...

Core Insights - The company reported a revenue of RMB 621 million for the six months ending June 30, 2025, representing a year-on-year growth of 51.3% [1] - Shareholder profit reached RMB 47.99 million, marking a turnaround from loss to profit, with earnings per share at RMB 0.12 [1] Group 1: Business Performance - The preclinical products and services segment, centered on innovative animal model sales, generated RMB 458 million in revenue, a 56.9% increase compared to the same period last year, with a gross margin of approximately 70% [1] - The antibody discovery business achieved RMB 163 million in revenue, a 37.8% increase year-on-year, with a gross margin of around 90% [2] - The company signed approximately 280 agreements for therapeutic antibodies and various clinical asset collaborations, with 80 new contracts signed in the first half of 2025, a 60% increase year-on-year [2] Group 2: Market Expansion - The company expanded its overseas market presence, achieving RMB 422 million in revenue from international operations, while domestic business also saw rapid growth with RMB 200 million in revenue [2] - The global network established by the company enhances its resilience and risk management capabilities, allowing for steady growth through market cycles [2] Group 3: Research and Development - The company maintained a high level of R&D investment, with R&D expenses amounting to RMB 209 million, an increase of RMB 47.74 million year-on-year, resulting in an R&D expense ratio exceeding 30% [3] - The company implemented lean management practices, leading to a continuous decline in management expense ratios, with significant results from cost-saving measures initiated in 2023 [3]